D3

Neros Technologies specializes in autonomous drone services aimed at enhancing defense capabilities. The company has developed a technology-based platform that focuses on keeping personnel off the battlefield, addressing vulnerabilities faced by dismounted soldiers in combat situations. By leveraging advanced drone technology, Neros Technologies seeks to provide innovative solutions that empower clients in the defense sector, helping to improve safety and operational effectiveness against armored threats.

Alpha Fusion specializes in the development of astatine-based radiopharmaceuticals for targeted alpha therapy, focusing on innovative cancer treatment solutions. The company is engaged in drug discovery and business development of low-molecular-weight and antibody-introduced astatine compounds. By harnessing alpha-ray nuclear medicine therapy, Alpha Fusion aims to provide healthcare providers with effective tools to combat cancer, enhancing treatment options for patients.

RevolKa is a biotechnology company focused on developing bio-products and pharmaceuticals for the healthcare sector. The firm aims to enhance global health by cultivating and evolving proteins, which are essential components of its bio-products. Utilizing artificial intelligence, RevolKa empowers medical researchers to deliver reliable and efficient medical services. Through its innovative approach, the company seeks to make significant contributions to public health and well-being.

Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.

RevolKa is a biotechnology company focused on developing bio-products and pharmaceuticals for the healthcare sector. The firm aims to enhance global health by cultivating and evolving proteins, which are essential components of its bio-products. Utilizing artificial intelligence, RevolKa empowers medical researchers to deliver reliable and efficient medical services. Through its innovative approach, the company seeks to make significant contributions to public health and well-being.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

B4A provides DX tool for medical clinics that helps with reservation, customer management, and data analysis.

iSiP is a company that creates AI and machine-learning products to improve the efficiency of the drug discovery process.